New York, NY – According to filings with the U.S. Securities and Exchange Commission, Inspirna is raising $55,096,738.00 in new funding. Sources indicate as part of senior management Chief Operating Officer, David Darst played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inspirna
Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirnas founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform which can be applied to virtually any tumor type has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies.

To learn more about Inspirna, visit http://www.inspirna.com/

Contact:
David Darst, Chief Operating Officer
646-856-9261
david.darst@inspirna.com
https://www.linkedin.com/in/davidmdarst/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved